Department of Family and Preventive Medicine,University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0622, USA.
Health Serv Res. 2012 Dec;47(6):2137-58. doi: 10.1111/j.1475-6773.2012.01427.x. Epub 2012 May 11.
Medical groups have invested billions of dollars in electronic medical records (EMRs), but few studies have examined the cost-effectiveness of EMR-based clinical decision support (CDS). This study examined the cost-effectiveness of EMR-based CDS for adults with diabetes from the perspective of the health care system.
DATA SOURCES/SETTING: Clinical outcome and cost data from a randomized clinical trial of EMR-based CDS were used as inputs into a diabetes simulation model. The simulation cohort included 1,092 patients with diabetes with A1c above goal at baseline.
The United Kingdom Prospective Diabetes Study Outcomes Model, a validated simulation model of diabetes, was used to evaluate remaining life years, quality-adjusted life years (QALYs), and health care costs over patient lifetimes (40-year time horizon) from the health system perspective.
Patients in the intervention group had significantly lowered A1c (0.26 percent, p = .014) relative to patients in the control arm. Intervention costs were $120 (SE = 45) per patient in the first year and $76 (SE = 45) per patient in the following years. In the base case analysis, EMR-based CDS increased lifetime QALYs by 0.04 (SE = 0.01) and increased lifetime costs by $112 (SE = 660), resulting in an incremental cost-effectiveness ratio of $3,017 per QALY. The cost-effectiveness of EMR-based CDS persisted in one-way, two-way, and probabilistic sensitivity analyses.
Widespread adoption of sophisticated EMR-based CDS has the potential to modestly improve the quality of care for patients with chronic conditions without substantially increasing costs to the health care system.
医疗团体已在电子病历(EMR)上投入了数十亿美元,但很少有研究评估基于 EMR 的临床决策支持(CDS)的成本效益。本研究从医疗保健系统的角度,评估了基于 EMR 的 CDS 对糖尿病成人患者的成本效益。
数据来源/设置:基于 EMR 的 CDS 的随机临床试验的临床结果和成本数据被用作糖尿病模拟模型的输入。模拟队列包括 1092 名基线时糖化血红蛋白(A1c)高于目标的糖尿病患者。
采用经过验证的糖尿病模拟模型——英国前瞻性糖尿病研究结果模型,从医疗保健系统的角度评估患者终生(40 年时间范围)的剩余寿命、质量调整生命年(QALY)和医疗保健成本。
与对照组相比,干预组患者的 A1c 显著降低(0.26%,p = 0.014)。干预组第一年的患者成本为 120 美元(SE = 45 美元),随后每年为 76 美元(SE = 45 美元)。在基本案例分析中,基于 EMR 的 CDS 增加了 0.04(SE = 0.01)个终生 QALY,并增加了 112 美元(SE = 660 美元)的终生成本,导致增量成本效益比为 3017 美元/QALY。基于 EMR 的 CDS 的成本效益在单向、双向和概率敏感性分析中仍然成立。
广泛采用复杂的基于 EMR 的 CDS 有可能在不显著增加医疗保健系统成本的情况下,适度改善慢性病患者的护理质量。